Scott M Lippman

Trials

Studies that name Scott M Lippman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:30 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05237960 · Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

  University of Arizona · active not recruiting · Erythroplakia, Oral Leukoplakia · principal investigator
• Ph2
  NCT02581137 · Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

  National Cancer Institute (NCI) · active not recruiting · Erythroplakia, Hyperplasia, Oral Cavity Carcinoma · principal investigator
• Ph2
  NCT00321893 · Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer

  National Cancer Institute (NCI) · completed · Lung Cancer · study chair
• N/A
  NCT00288106 · S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT

  SWOG Cancer Research Network · terminated · Prostate Cancer · study chair
• Ph3
  NCT00006392 · S0000 Selenium and Vitamin E in Preventing Prostate Cancer

  SWOG Cancer Research Network · completed · Prostate Cancer · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transition
  U01CA290479 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2023 to 2026 · $790,000 awarded in 2026
  Same name and institution; not confirmed by an ID
• Targeting Signaling Vulnerabilities for Oral Cancer Prevention
  R01DE026644 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2017 to 2026 · $475,111 awarded in 2026
  Same name and institution; not confirmed by an ID
• Developmental Funds
  P30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2011 to 2023 · $614,904 awarded in 2023
  Same name and institution; not confirmed by an ID
• CA: Administrative Core
  P50CA097007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2007 to 2012 · $183,834 awarded in 2012
  Same name and institution; not confirmed by an ID
• Insulin-like Growth Factor Axis and Insulin Resistance in PCPT
  P01CA108964 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2005 to 2009 · $59,092 awarded in 2009
  Same name and institution; not confirmed by an ID
• Molecular-Based Therapy for Oral Cancer Prevention
  P01CA106451 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2004 to 2009 · $1,247,244 awarded in 2009
  Same name and institution; not confirmed by an ID
• Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive Agents
  N01CN35159- · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2007 to 2009 · $2,136,000 awarded in 2009
  Same name and institution; not confirmed by an ID
• U10 Ful Member Application Affiliated with SWOG
  U10CA105409 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2004 to 2008 · $71,573 awarded in 2008
  Same name and institution; not confirmed by an ID
• PHASE 1 PHARMACODYNAMIC STUDY OF COX-2 INHIBITION AND AROMATASE ACTIVI-261035112
  N01CN035112 · NCI · M. D. ANDERSON CANCER CENTER · fiscal years 2004 to 2006
  Same name and institution; not confirmed by an ID
• PHASE I and II CLINICAL TRIALS OF CHEMOPREVENTIVE AGENTS-261035159-261035159
  N01CN035159 · NCI · UNIVERSITY OF TEXAS M D ANDER · fiscal years 2004 to 2006
  Same name and institution; not confirmed by an ID
• PHASE 1 PHARMACODYNAMIC STUDY OF COX-2 INHIBITION AND AROMATASE ACTIVI-261035112
  N01CA035112 · NCI · M. D. ANDERSON CANCER CENTER · fiscal years 2003
  Same name and institution; not confirmed by an ID
• BIOLOGIC APPROACH TO THERAPY OF AGGRESSIVE SKIN CANCER
  P01CA068233 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 1996 to 2002 · $196,218 awarded in 2002
  Same name and institution; not confirmed by an ID
• PHASE III STUDY OF FENRETINIDE IN BLADDER CARCINOFENESIS
  U01CA077150 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 1997 to 2001 · $449,646 awarded in 2001
  Same name and institution; not confirmed by an ID
• TRANSLATIONAL STUDY OF RETINOID REVERSAL OR ORAL CARCINOGENESIS
  P01CA052051 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 1996 to 2000 · $245,933 awarded in 2000
  Same name and institution; not confirmed by an ID
• PHASE II CLINICAL TRIALS OF NEW CHEMOPRVENTIVE AGENTS
  N01CN065004 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 1998 to 1999
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Cancer Biology Program (CBP)
  P30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Koenraad Van Doorslaer · fiscal years 2004 to 2026
  Named on NCT05237960, NCT02581137
• University of Arizona Cancer Prevention Clinical Trials Network
  UG1CA242596 · NCI · UNIVERSITY OF ARIZONA · PI Julie E Bauman, Patricia Ann Thompson · fiscal years 2019 to 2026
  Named on NCT05237960
• NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT
  U10CA012027 · NCI · NSABP FOUNDATION, INC. · PI NORMAN WOLMARK · fiscal years 2005 to 2012
  Named on NCT00288106
• SWOG Community Clinical Oncology Program Research Base
  U10CA037429 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI CHARLES D. BLANKE, FRANK L. MEYSKENS · fiscal years 2004 to 2014
  Named on NCT00006392